TIME

How a discontinued Alzheimer’s drug study got a second life

“MY FIRST REACTION WAS TO BE ANGRY,” SAYS JOANN Wooding. “I’ve gotten over that, and is more the word right now.” Wooding’s husband Peter, who was diagnosed with Alzheimer’s in 2016, was among the more than 3,200 people with the disease who volunteered to test a promising drug called aducanumab. In earlier study results released the same year, the drug, developed by Biogen, a U.S. biotech company, and Eisai, a Japanese pharmaceutical manufacturer, seemed to accomplish a number of firsts for people with Alzheimer’s. It appeared to shrink deposits of the protein amyloid accumulating in the brains of patients and, perhaps more important, also slow the cognitive decline

You're reading a preview, sign up to read more.

More from TIME

TIME2 min readSociety
Has The CDC Finally Figured Out What’s Making Vapers Sick?
SINCE THE U.S. CENTERS FOR DISEASE Control and Prevention (CDC) first announced an outbreak of vaping-related lung diseases in August, the agency has faithfully provided updates as the number of people diagnosed with these illnesses ticks up and up,
TIME5 min readPolitics
Amy Klobuchar
IT’S A BRISK SATURDAY MORNING IN NOVEMBER, and Amy Klobuchar is pondering the menu at a Sioux City, Iowa, diner where a dish of two buttermilk biscuits smothered in country-style gravy is listed among the “lite” breakfasts. The Minnesota Democrat usu
TIME3 min read
From the Editor
WHEN WE FIRST PUBLISHED OUR TIME 100 LIST OF the world’s most influential people 15 years ago, it was dominated by individuals who rose through traditional power structures: heads of state, CEOs of public companies, actors from big-budget blockbuster